Literature DB >> 26021528

Renal Outcomes Following Fenestrated and Branched Endografting.

T Martin-Gonzalez1, C Pinçon2, B Maurel1, A Hertault1, J Sobocinski1, R Spear1, M Le Roux1, R Azzaoui1, T M Mastracci3, S Haulon4.   

Abstract

OBJECTIVE: The purpose of this study was to analyze immediate and long-term renal outcomes (renal function and renal events) after fenestrated (FEVAR) and branched endovascular aortic aneurysm repair (BEVAR).
METHODS: All FEVAR and BEVAR performed between October 2004 and October 2012 were included in this study. Post-operative acute renal failure (ARF) was defined according to the RIFLE criteria. Renal volume (calculated with a 3D workstation) and estimated glomerular filtration rate (GFR) (estimated with the Modification of Diet in Renal Disease [MDRD] formula) were evaluated before the procedure, before discharge, 12 months after, and yearly thereafter. Renal stent occlusion, dissection, fracture, stenosis, kink, renal stent related endoleak, and renal stent secondary intervention were all considered "renal composite events" and analyzed. A time to event analysis was performed for renal events and secondary renal interventions.
RESULTS: 225 patients were treated with FEVAR and BEVAR. Renal target vessels (n = 427) were perfused by fenestrations (n = 374), or branches (n = 53). Median follow up was 3.1 years (2.9-3.3 years). Technical success was achieved in 95.5% of patients. Post-operative ARF was seen in 64 patients (29%). Mean total renal volume and eGFR at 1 year, 2 year, and 3 year follow up were significantly lower when compared with pre-operative levels (after BEVAR and FEVAR); the decrease at 3 years was 14.8% (6.7%; 22.2%) (p = .0006) for total renal volume and 14.3% (3.1%; 24.3%) (p = .02) for eGFR. The 30 day and 5 year freedom from renal composite event was 98.6% (95.8-99.6%) and 84.5% (76.5-89.9%) after FEVAR and BEVAR (NS). The 30 day and 5 year freedom from renal occlusion was 99.5% (96.7-99.9%) and 94.4% (89.3-97.1%) after FEVAR and BEVAR (NS).
CONCLUSION: FEVAR and BEVAR are durable options for the treatment of complex aortic aneurysms and are associated with low renal morbidity, without differences between devices types. The clinical impact of decreasing renal volume over time in these patients is yet to be fully understood.
Copyright © 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BEVAR; FEVAR; Outcome; Renal; Thoraco-abdominal aneurysm; Volume

Mesh:

Year:  2015        PMID: 26021528     DOI: 10.1016/j.ejvs.2015.04.011

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  4 in total

1.  Perioperative outcome of endovascular repair for complex abdominal aortic aneurysms.

Authors:  Klaas H J Ultee; Sara L Zettervall; Peter A Soden; Jeremy Darling; Hence J M Verhagen; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2017-02-16       Impact factor: 4.268

2.  Stroke volume variation and serum creatinine changes during abdominal aortic aneurysm surgery: a time-integrated analysis.

Authors:  Paolo Lentini; Luca Zanoli; Pasquale Fatuzzo; Faeq Husain-Syed; Rudi Stramanà; Diego Cognolato; Vincenzo Catena; Marco Baiocchi; Antonio Granata; Roberto Dell'Aquila
Journal:  J Nephrol       Date:  2018-01-17       Impact factor: 3.902

3.  The bio-sonographic index. A novel modality for early detection of acute kidney injury after complex vascular surgery. A protocol for an exploratory prospective study.

Authors:  Ahmed Zaky; Adam W Beck; Sejong Bae; Adam Sturdivant; Amandiy Liwo; Novak Zdenek; Nicole McAnally; Shama Ahmad; Brad Meers; Michelle Robbin; J F Pittet; Ashita Tolwani; Dan Berkowitz
Journal:  PLoS One       Date:  2020-11-17       Impact factor: 3.240

4.  Incidence of Acute and Chronic Renal Failure Following Branched Endovascular Repair of Complex Aortic Aneurysms.

Authors:  Matthew J Lommen; Jack J Vogel; Angela VandenHull; Valerie Reed; Kathryn Pohlson; Geoffrey A Answini; Thomas S Maldonado; Thomas C Naslund; Murray L Shames; Patrick W Kelly
Journal:  Ann Vasc Surg       Date:  2021-06-25       Impact factor: 1.466

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.